A CRUK phase I/IIA, first in human dose-escalation and expansion trial of HMBD-001 (an anti-HER-3 antibody) in patients with advanced HER3-positive solid tumours

被引：0

作者：

de Bono, J. S. ^{[1
]}

Lord, S. ^{[2
]}

Yap, C. ^{[3
]}

Rowinsky, E. K. ^{[4
]}

Gandhi, N. A. ^{[4
]}

Thakkar, D. ^{[5
]}

Ingram, P. J. ^{[5
]}

Padmanabhan, N. ^{[6
]}

Chandran, K. ^{[7
,8
]}

Paschalis, A. ^{[9
]}

McGuigan, L. ^{[10
]}

Neal, P. ^{[10
]}

Paisley, D. ^{[10
]}

Walter, H. S. ^{[10
]}

Kelly, F. ^{[10
]}

Craigan, J. ^{[10
]}

Westwood, N. B. ^{[10
]}

Halbert, G. ^{[10
]}

Boyd-Kirkup, J. D. ^{[11
]}

Halford, S. E. R. ^{[10
]}

机构：

[1] ICR Inst Canc Res, London, England

[2] Univ Oxford, Oncol, Oxford, England

[3] ICR Inst Canc Res North Site, Clin Trials Biostat Dept, Sutton, England

[4] Hummingbird Biosci, Dis Area Strategy, Houston, TX USA

[5] Hummingbird Biosci Pte Ltd, Pharmacol Dept, Temasek Lifesci Labs, Singapore, Singapore

[6] Hummingbird Biosci Pte Ltd, Pharmacol, Temasek Lifesci Labs, Singapore, Singapore

[7] Inst Canc Res, Med Oncol, Sutton, England

[8] Royal Marsden Hosp, Sutton, England

[9] ICR Inst Canc Res, Clin Studies, London, England

[10] CRUK Canc Res UK, Ctr Drug Dev, London, England

[11] Hummingbird Biosci Pte Ltd, Res, Temasek Lifesci Labs, Singapore, Singapore

来源：

ANNALS OF ONCOLOGY | 2022年 / 33卷 / 07期

关键词：

D O I：

10.1016/j.annonc.2022.07.621

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

493TiP

引用

页码：S767 / S767

页数：1

共 50 条

[31] DB-1310, an ADC comprised of a novel anti-HER3 antibody conjugated to a DNA topoisomerase I inhibitor, is highly effective for the treatment of HER3-positive solid tumors
Li, Xi
Yao, Jun
Qu, Chen
Luo, Lan
Li, Bing
Zhang, Yu
Zhu, Zhongyuan
Qiu, Yang
Hua, Haiqing
JOURNAL OF TRANSLATIONAL MEDICINE, 2024, 22 (01)
[32] Phase I dose-escalation trial with the DNA-alkylating anti-HER2 antibody-drug conjugate SYD985
Van Herpen, C. M.
Banerji, U.
Mommers, E. C.
Koper, N. P.
Goedings, P.
Lopez, J.
Awada, A.
Fiebrich, H. B.
Aftimos, P. G.
EUROPEAN JOURNAL OF CANCER, 2015, 51 : S65 - S65
[33] First-in-Human, Multicenter, Phase I Dose-Escalation and Expansion Study of Anti-Mesothelin Antibody-Drug Conjugate Anetumab Ravtansine in Advanced or Metastatic Solid Tumors
Hassan, Raffit
Blumenschein, George R., Jr.
Moore, Kathleen N.
Santin, Alessandro D.
Kindler, Hedy L.
Nemunaitis, John J.
Seward, Shelly M.
Thomas, Anish
Kim, Stella K.
Rajagopalan, Prabhu
Walter, Annette O.
Laurent, Dirk
Childs, Barrett H.
Sarapa, Nenad
Elbi, Cem
Bendell, Johanna C.
JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (16) : 1824 - +
[34] Phase I study of TrasGEX, a glyco-optimised anti-HER2 monoclonal antibody, in patients with HER2-positive solid tumours
Fiedler, Walter
Stoeger, Herbert
Perotti, Antonella
Gastl, Guenther
Weidmann, Jens
Dietrich, Bruno
Baumeister, Hans
Danielczyk, Antje
Goletz, Steffen
Salzberg, Marc
De Dosso, Sara
ESMO OPEN, 2018, 3 (04)
[35] A phase I, first-in-human, dose-escalation and dose expansion study of the multitarget kinase inhibitor TT-00420 in patients with advanced solid tumors.
Piha-Paul, Sarina Anne
Wan, Qunfang
Xiong, Wendy
Peng, Peng
Yang, Xiaoju
Wu, Henry
Ngo, Brenda
Wu, Frank
JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
[36] Phase I dose-escalation trial of Sym004, an anti-EGFR antibody mixture, in Japanese patients with advanced solidtumors
Kojima, Takashi
Yamazaki, Kentaro
Kato, Ken
Muro, Kei
Hara, Hiroki
Chin, Keisho
Goddemeier, Thomas
Kuffel, Stefan
Watanabe, Morihiro
Doi, Toshihiko
CANCER SCIENCE, 2018, 109 (10): : 3253 - 3262
[37] PHASE I AND DOSE FINDING STUDY OF U3-1287, A HUMAN MONOCLONAL ANTIBODY TARGETING HER3, IN JAPANESE PATIENTS WITH ADVANCED SOLID TUMORS
Wakui, H.
Yamamoto, N.
Nakamichi, S.
Tamura, Y.
Nokihara, H.
Yamada, Y.
Tamura, T.
ANNALS OF ONCOLOGY, 2012, 23 : 112 - 112
[38] First-in-Human Phase I, Dose-Escalation and -Expansion Study of Telisotuzumab Vedotin, an Antibody-Drug Conjugate Targeting c-Met, in Patients With Advanced Solid Tumors
Strickler, John H.
Weekes, Colin D.
Nemunaitis, John
Ramanathan, Ramesh K.
Heist, Rebecca S.
Morgensztern, Daniel
Angevin, Eric
Bauer, Todd M.
Yue, Huibin
Motwani, Monica
Parikh, Apurvasena
Reilly, Edward B.
Afar, Daniel
Naumovski, Louie
Kelly, Karen
JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (33) : 3298 - +
[39] Phase I, first-in-human, open-label, dose-escalation study of U3-1565, a fully human anti-HB-EGF monoclonal antibody, in patients with advanced solid tumors.
Moore, Kathleen N.
Bendell, Johanna C.
Olszanski, Anthony J.
Desai, Madhuri
Jansen, Mendel
Scheyer, Richard David
Senaldi, Giorgio
LoRusso, Patricia
JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
[40] HLX22, an anti-HER-2 monoclonal antibody, in patients with advanced solid tumors overexpressing human epidermal growth factor receptor 2: an open-label, dose-escalation, phase 1 trial
Xiaoxue Zhu
Yanhua Ding
Qian Wang
Guiyu Yang
Liang Zhou
Qingyu Wang
Investigational New Drugs, 2023, 41 : 473 - 482

← 1 2 3 4 5 →